Education
About Us
Working with TipRanks
Follow Us
Bicycle Therapeutics (BCYC)
:BCYC
BCYC Analyst Ratings
Strong Buy
7 Buy
2 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
BCYC Stock 12 Month Forecast
Average Price Target
$23.25
▲(212.50% Upside)
| Highest Price Target$44.00 | Average Price Target$23.25 | Lowest Price Target$7.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TR | OpenAI - 4o
$8→$7
Hold
-5.91%
Downside
Reiterated
08/15/25
Morgan Stanley
$17→$13
Hold
74.73%
Upside
Reiterated
08/12/25
Citizens JMP
$22→$10
Buy
34.41%
Upside
Reiterated
08/12/25
H.C. Wainwright
$33
Buy
343.55%
Upside
Reiterated
08/11/25
Oppenheimer
$48→$44
Buy
491.40%
Upside
Reiterated
08/11/25
Leerink Partners
$24
Buy
222.58%
Upside
Reiterated
08/11/25
Needham
$28
Buy
276.34%
Upside
Reiterated
08/08/25
RBC Capital
$27
Buy
262.90%
Upside
Reiterated
08/08/25
TD Cowen
―
Buy
―
Reiterated
08/08/25
TD Cowen Reaffirms Their Buy Rating on Bicycle Therapeutics (BCYC)We expect a topline update on dose selection from DV-2 and the potential path forward for accelerated approval after the company meets with the FDA in Q4. Also in H2, we should get a Phase II 1L update (with the same data cutoff) and a 2L+ update likely including mPFS. The Street would like to see it beat Padcev's ~5.5 months, but similar efficacy with differentiated safety could be successful.
B.Riley Financial
$17→$14
Hold
88.17%
Upside
Reiterated
05/02/25
Barclays
$40→$15
Buy
101.61%
Upside
Reiterated
05/01/25
Jefferies
$42
Buy
464.52%
Upside
Reiterated
02/25/25
Bicycle Therapeutics: Promising Clinical Advances and Strong Financial Position Support Buy RatingWe believe the data support its unique MOA w/ small peptide radioligands. Co will report add'l MT1-MMP human imaging data in mid'25 and initial EphA2 human imaging data in 2H25. BCYC aims to start the first clinical trial for its first BRC program in 2026. Q4'24 Financials. As of 12/31/24, co had $879.5M in cash and cash equivalents to provide runway into 2H27.
Rodman & Renshaw
$33
Buy
343.55%
Upside
Reiterated
02/25/25
Stephens
$25
Hold
236.02%
Upside
Initiated
11/07/24
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TR | OpenAI - 4o
$8→$7
Hold
-5.91%
Downside
Reiterated
08/15/25
Morgan Stanley
$17→$13
Hold
74.73%
Upside
Reiterated
08/12/25
Citizens JMP
$22→$10
Buy
34.41%
Upside
Reiterated
08/12/25
H.C. Wainwright
$33
Buy
343.55%
Upside
Reiterated
08/11/25
Oppenheimer
$48→$44
Buy
491.40%
Upside
Reiterated
08/11/25
Leerink Partners
$24
Buy
222.58%
Upside
Reiterated
08/11/25
Needham
$28
Buy
276.34%
Upside
Reiterated
08/08/25
RBC Capital
$27
Buy
262.90%
Upside
Reiterated
08/08/25
TD Cowen
―
Buy
―
Reiterated
08/08/25
TD Cowen Reaffirms Their Buy Rating on Bicycle Therapeutics (BCYC)We expect a topline update on dose selection from DV-2 and the potential path forward for accelerated approval after the company meets with the FDA in Q4. Also in H2, we should get a Phase II 1L update (with the same data cutoff) and a 2L+ update likely including mPFS. The Street would like to see it beat Padcev's ~5.5 months, but similar efficacy with differentiated safety could be successful.
B.Riley Financial
$17→$14
Hold
88.17%
Upside
Reiterated
05/02/25
Barclays
$40→$15
Buy
101.61%
Upside
Reiterated
05/01/25
Jefferies
$42
Buy
464.52%
Upside
Reiterated
02/25/25
Bicycle Therapeutics: Promising Clinical Advances and Strong Financial Position Support Buy RatingWe believe the data support its unique MOA w/ small peptide radioligands. Co will report add'l MT1-MMP human imaging data in mid'25 and initial EphA2 human imaging data in 2H25. BCYC aims to start the first clinical trial for its first BRC program in 2026. Q4'24 Financials. As of 12/31/24, co had $879.5M in cash and cash equivalents to provide runway into 2H27.
Rodman & Renshaw
$33
Buy
343.55%
Upside
Reiterated
02/25/25
Stephens
$25
Hold
236.02%
Upside
Initiated
11/07/24
Best Analysts Covering Bicycle Therapeutics
1 Month
xxx
Success Rate
8/17 ratings generated profit
Average Return
+1.95%
reiterated a xxx
rating 7 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 47.06% of your transactions generating a profit, with an average return of +1.95% per trade.
3 Months
xxx
Success Rate
9/17 ratings generated profit
Average Return
+7.42%
reiterated a xxx
rating 7 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 52.94% of your transactions generating a profit, with an average return of +7.42% per trade.
1 Year
2 Years
xxx
Success Rate
2/17 ratings generated profit
Average Return
-41.75%
reiterated a xxx
rating 7 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 11.76% of your transactions generating a profit, with an average return of -41.75% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
BCYC Analyst Recommendation Trends
Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
11
8
7
6
6
Buy
1
2
3
3
3
Hold
6
9
11
11
8
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
18
19
21
20
17
Each month's total comprises the sum of three months' worth of ratings.
BCYC Financial Forecast
BCYC Stock Forecast FAQ
What is BCYC’s average 12-month price target, according to analysts?
Based on analyst ratings, Bicycle Therapeutics’s 12-month average price target is 23.25.
What is BCYC’s upside potential, based on the analysts’ average price target?
Bicycle Therapeutics has 212.50% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is BCYC a Buy, Sell or Hold?
Bicycle Therapeutics has a consensus rating of Strong Buy which is based on 7 buy ratings, 2 hold ratings and 0 sell ratings.
What is Bicycle Therapeutics’s price target?
The average price target for Bicycle Therapeutics is 23.25. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $44.00 ,the lowest forecast is $7.00. The average price target represents 212.50% Increase from the current price of $7.44.
The highest analyst price target is $44.00 ,the lowest forecast is $7.00. The average price target represents 212.50% Increase from the current price of $7.44.
What do analysts say about Bicycle Therapeutics?
Bicycle Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.
How can I buy shares of BCYC?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.